ATE211767T1 - Dämpfung eines immundominanten epitops eines antigens zur verwendung für pflanzen, tierische und menschliche impstoffe und immuntherapien - Google Patents

Dämpfung eines immundominanten epitops eines antigens zur verwendung für pflanzen, tierische und menschliche impstoffe und immuntherapien

Info

Publication number
ATE211767T1
ATE211767T1 AT94925937T AT94925937T ATE211767T1 AT E211767 T1 ATE211767 T1 AT E211767T1 AT 94925937 T AT94925937 T AT 94925937T AT 94925937 T AT94925937 T AT 94925937T AT E211767 T1 ATE211767 T1 AT E211767T1
Authority
AT
Austria
Prior art keywords
epitope
antigen
immunodominating
immunotherapies
attenuation
Prior art date
Application number
AT94925937T
Other languages
English (en)
Inventor
Robert R Garrity
Peter L Nara
Jaap Goudsmit
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE211767T1 publication Critical patent/ATE211767T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94925937T 1993-08-20 1994-08-19 Dämpfung eines immundominanten epitops eines antigens zur verwendung für pflanzen, tierische und menschliche impstoffe und immuntherapien ATE211767T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/109,934 US5585250A (en) 1993-08-20 1993-08-20 Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
PCT/US1994/009336 WO1995006124A1 (en) 1993-08-20 1994-08-19 Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies

Publications (1)

Publication Number Publication Date
ATE211767T1 true ATE211767T1 (de) 2002-01-15

Family

ID=22330363

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94925937T ATE211767T1 (de) 1993-08-20 1994-08-19 Dämpfung eines immundominanten epitops eines antigens zur verwendung für pflanzen, tierische und menschliche impstoffe und immuntherapien

Country Status (11)

Country Link
US (2) US5585250A (de)
EP (1) EP0714444B1 (de)
JP (2) JP3851938B2 (de)
AT (1) ATE211767T1 (de)
AU (1) AU700786B2 (de)
CA (2) CA2623540A1 (de)
DE (1) DE69429625T2 (de)
DK (1) DK0714444T3 (de)
ES (1) ES2170771T3 (de)
PT (1) PT714444E (de)
WO (1) WO1995006124A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies
WO1997017372A1 (en) * 1995-11-03 1997-05-15 The Binding Site Limited Production of antibodies, and medical uses involving antibodies
US6936249B1 (en) * 1998-04-15 2005-08-30 Genencor International, Inc. Proteins producing an altered immunogenic response and methods of making and using the same
US6642011B2 (en) * 1998-04-15 2003-11-04 Genencor International, Inc. Human protease and use of such protease for pharmaceutical applications and for reducing the allergenicity of non-human proteins
US6835550B1 (en) * 1998-04-15 2004-12-28 Genencor International, Inc. Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins
US20020182180A1 (en) * 1998-05-29 2002-12-05 Yutaro Kaneko Method for inducing immunity to viruses
CA2348822A1 (en) * 1998-10-30 2000-05-11 Novozymes A/S Glycosylated proteins having reduced allergenicity
US6759216B1 (en) * 1998-11-06 2004-07-06 Emory University Glycosylated, low antigenicity low immunogenicity factor VIII
US7078043B2 (en) 1999-04-20 2006-07-18 Medical Research Council Malaria vaccine
DE10055786A1 (de) * 2000-11-10 2002-05-29 Henkel Kgaa Haftungsverstärker für monomerfreie reaktive Polyurethane
AU774286B2 (en) 1999-11-29 2004-06-24 Henkel Kommanditgesellschaft Auf Aktien Adhesion promoters for monomer-free reactive polyurethanes
US6673580B2 (en) * 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
AU2003300870A1 (en) * 2002-12-11 2004-06-30 The Scripps Research Institute Immunogenic mutant human immunodeficiency virus gp120 polypeptides, and methods of using same
US7514539B2 (en) * 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US7790405B2 (en) * 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
AU2005271893A1 (en) * 2004-07-10 2006-02-16 Alexion Pharmaceuticals, Inc. Antibodies against cancer produced using masked cancer cells as immunogen
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1868652A2 (de) * 2005-04-05 2007-12-26 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Verfahren zur abschirmung von funktionalen stellen oder epitopen auf proteinen
US20090162383A1 (en) * 2006-12-26 2009-06-25 Padlan Eduardo A Method for designing vaccines against constantly mutating pathogens
EP2254593B1 (de) * 2008-02-21 2018-09-05 Biological Mimetics, Inc. Immunogene influenza-zusammensetzung
US9782472B2 (en) * 2008-10-04 2017-10-10 The Regents Of The University Of California Therapeutic compositions and methods for treating HIV including identification and manipulation of particular domains associated with immunogenicity
NZ604943A (en) * 2008-12-02 2014-08-29 Consejo Nac Invest Cient Tec Modified protozoan expressing at least two variable surface proteins (vsp), a vaccine comprising it and procedures, uses, and methods thereof
US20100189727A1 (en) * 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
WO2011028963A2 (en) * 2009-09-03 2011-03-10 Biological Mimetics, Inc. Immunogenic hiv composition
CA2787974A1 (en) 2010-01-24 2011-07-28 Biological Mimetics, Inc. Immunogenic influenza composition
WO2011119920A2 (en) 2010-03-25 2011-09-29 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
AU2011344126B2 (en) 2010-12-13 2016-11-10 The University Of Utah Research Foundation Vaccine antigens that direct immunity to conserved epitopes
ES2667425T3 (es) 2011-06-10 2018-05-10 Oregon Health & Science University Glucoproteínas y vectores recombinantes de CMV
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
EP3269728B1 (de) 2011-10-20 2020-12-16 The Government of The United States of America as represented by The Secretary, Department of Health and Human Services E-glycoprotein-polypeptide des dengue-virus mit mutationen zur eliminierung von immundominanten kreuzreaktiven epitopen
EP2586461A1 (de) 2011-10-27 2013-05-01 Christopher L. Parks Von einem eingehüllten Virus abgeleitete Virenpartikel
EP2679596B1 (de) 2012-06-27 2017-04-12 International Aids Vaccine Initiative HIV-1 Env-proteinvariante
JP6467672B2 (ja) 2012-07-17 2019-02-13 メリアル インコーポレイテッド 弱毒ブタインフルエンザワクチンならびにその製造方法および使用方法
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP2873423B1 (de) 2013-10-07 2017-05-31 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
SG10201806481XA (en) * 2014-02-19 2018-09-27 Emergent Biosolutions Canada Inc Marburg monoclonal antibodies
CA2952741A1 (en) 2014-06-26 2015-12-30 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
EP3072901A1 (de) 2015-03-23 2016-09-28 International Aids Vaccine Initiative Lösliche hiv-1-hüllglykoproteintrimere
JP7614841B2 (ja) * 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (de) 2018-04-03 2021-02-17 Sanofi Ferritinproteine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5041376A (en) * 1988-12-09 1991-08-20 The Board Of Regents Of The University Of Texas System Method for identifying or shielding functional sites or epitopes of proteins that enter the exocytotic pathway of eukaryotic cells, the mutant proteins so produced and genes encoding said mutant proteins
US5585250A (en) * 1993-08-20 1996-12-17 The United States Of America As Represented By The Department Of Health & Human Services Dampening of an immunodominant epitope of an antigen for use in plant, animal and human compositions and immunotherapies

Also Published As

Publication number Publication date
AU700786B2 (en) 1999-01-14
US5585250A (en) 1996-12-17
EP0714444A1 (de) 1996-06-05
CA2623540A1 (en) 1995-03-02
JP2006104216A (ja) 2006-04-20
WO1995006124A1 (en) 1995-03-02
US5853724A (en) 1998-12-29
DE69429625T2 (de) 2002-09-12
ES2170771T3 (es) 2002-08-16
DK0714444T3 (da) 2002-04-29
CA2169764C (en) 2008-04-15
JPH09501933A (ja) 1997-02-25
DE69429625D1 (de) 2002-02-14
PT714444E (pt) 2002-07-31
JP3851938B2 (ja) 2006-11-29
EP0714444B1 (de) 2002-01-09
AU7569294A (en) 1995-03-21
CA2169764A1 (en) 1995-03-02

Similar Documents

Publication Publication Date Title
DE69429625D1 (de) Dämpfung eines immundominanten epitops eines antigens zur verwendung für pflanzen, tierische und menschliche impstoffe und immuntherapien
ES2090332T3 (es) Tejido linfoide humano en un hospedador inmunocomprometido.
ES2191016T3 (es) Anticuerpos monoclonales neutralizantes humanos para el virus respiratorio sincitial.
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
IT1237764B (it) Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DE69533964D1 (de) Orale immunisierung durch verwendung von transgenen pflanzen
EE03031B1 (et) Kasvaja süsivesik-antigeeni spetsiifiline monokloonne antikeha, meetod in vitro diagnostikaks ja farmatseutilised kompositsioonid
ATE212233T1 (de) Impfstoffe gegen neisseria meningitidis gruppe c
AU7933891A (en) Process for enhancing the resistance of aquatic animals to disease
ATE124265T1 (de) Idiotypen-impfung gegen b-zell-lymphoma.
Phillips et al. In vivo T cell depletion regulates resistance and morbidity in murine schistosomiasis.
ATE78403T1 (de) Impfstoff gegen mastitis.
DE69821506D1 (de) Verwendung einer chemisch stabilisierten chloritlösung zur inhibition der antigenspezifischen immunantwort
Jungeblut Serological relationships within the poliomyelitis group of viruses
EP0585364A4 (de) Das durch den monoklonalen menschlichen antikörper 81av78 erkannte antigen ctaa 81av78.
ATE211923T1 (de) Parenterale immunisierung gegen rotavirus
FR2385401A1 (fr) Vaccin a virus respiratoire syncytial
Faulk et al. Vaccines and vaccination programs—special emphasis in malnutrition
DK0542895T3 (da) Krydsreaktiv influenza A immunisering
ATE156711T1 (de) Nicht-zellzahlverringernde cd4-spezifische monoklonale antikörper zur behandlung von insulinabhängigem diabetes mellitus (iddm)
ES471766A1 (es) Un procedimiento de preparacion de un virus vivo atenuado dela para-influenza
Sencer et al. Service, Silver Spring, Maryland
Deri The aged and women: Partners by prejudice.
MX171572B (es) Substancia que contiene anticuerpo especifico a partir de huevos y metodo de produccion y uso de la misma
Humphrey Comments on Use of Rabies Vaccines

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification